Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase((R)))
| dc.rights.license | open | en_US |
| dc.contributor.author | DUGA, Alemayehu Lelisa | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SALVO, Francesco
IDREF: 221043470 | |
| dc.contributor.author | KAY, Alexander | |
| dc.contributor.author | FIGUERAS, Albert | |
| dc.date.accessioned | 2023-06-26T07:08:50Z | |
| dc.date.available | 2023-06-26T07:08:50Z | |
| dc.date.issued | 2023-04-25 | |
| dc.identifier.issn | 2079-6382 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/182805 | |
| dc.description.abstractEn | BACKGROUND: The introduction of new drugs that increase the usage of repurposed medicines for managing drug-resistant tuberculosis (DR-TB) comes with challenges of understanding, properly managing, and predicting adverse drug reactions (ADRs). In addition to the health consequences of ADRs for the individual, ADRs can reduce treatment adherence, thus contributing to resistance. This study aimed to describe the magnitude and characteristics of DR-TB-related ADRs through an analysis of ADRs reported to the WHO database (VigiBase) in the period from January 2018 to December 2020. METHODS: A descriptive analysis was performed on selected reports from VigiBase on the basis of medicine-potential ADR pairs. The ADRs were stratified by sex, age group, reporting country, seriousness, outcome of the reaction, and dechallenge and rechallenge. RESULTS: In total, 25 medicines reported to be suspected individual medicines or as a fixed-dose combination in the study period were included the study. Pyrazinamide (n = 836; 11.2%) was the most commonly reported medicine associated with ADRs, followed by ethionamide (n = 783; 10.5%) and cycloserine (n = 696; 9.3%). From the report included in this analysis, 2334 (31.2%) required complete withdrawal of the suspected medicine(s), followed by reduction of the dose (77; 1.0%) and an increased dose (4; 0.1%). Almost half of the reports were serious ADRs mainly caused by bedaquiline, delamanid, clofazimine, linezolid, and cycloserine that are the backbone of the DR-TB treatment currently in use. CONCLUSIONS: A third of the reports required medication withdrawal, which impacts treatment adherence and ultimately leads to drug resistance. Additionally, more than 40% of the reports indicated that ADRs appeared two months after the commencement of treatment, thus it's important to remain alert for the potential ADRs for the entire duration of the treatment. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Drug-resistant tuberculosis | |
| dc.subject.en | Pharmacovigilance | |
| dc.subject.en | VigiBase® | |
| dc.subject.en | Adverse drug reaction | |
| dc.title.en | Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase((R))) | |
| dc.title.alternative | Antibiotics (Basel) | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/antibiotics12050811 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 37237714 | en_US |
| bordeaux.journal | Antibiotics | en_US |
| bordeaux.volume | 12 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 5 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04140693 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-06-26T07:08:54Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Antibiotics&rft.date=2023-04-25&rft.volume=12&rft.issue=5&rft.eissn=2079-6382&rft.issn=2079-6382&rft.au=DUGA,%20Alemayehu%20Lelisa&SALVO,%20Francesco&KAY,%20Alexander&FIGUERAS,%20Albert&rft.genre=article |
